🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

21 results for “Spero” Clear

  1. TBP-PI-HBr

    Spero Therapeutics

    Urinary Tract Infection

    phase 3 small molecule completed

    1 trial

  2. TBPM-PI-HBr

    Spero Therapeutics

    Complicated Urinary Tract Infection

    phase 3 small molecule completed

    1 trial

  3. Tebipenem pivoxil, SODIUM CHLORIDE, IMIPENEM AND CILASTATIN , Placebo to match Tebipenem pivoxil, tablet

    Spero Therapeutics

    complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  4. Placebo

    Spero Therapeutics

    Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

    phase 2 small molecule completed

    1 trial

  5. SPR720

    Spero Therapeutics

    Mycobacterium Avium Complex

    phase 2 small molecule terminated

    1 trial

  6. SPR206

    Spero Therapeutics

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  7. SPR206

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  8. SPR720

    Spero Therapeutics

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  9. SPR720

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. SPR720 for SAD

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. SPR741

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  12. SPR994

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. TBP-PI-HBr

    Spero Therapeutics

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  14. TBP-PI-HBr

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  15. TBPM-PI-HBr

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    3 trials

  16. Tebipenem Pivoxil Hydrobromide

    Spero Therapeutics

    Diabetes

    phase 1 small molecule completed

    1 trial

  17. Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo

    Spero Therapeutics

    TQT Study

    phase 1 small molecule completed

    1 trial

  18. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

    Spero Therapeutics

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  20. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. Tebipenem tablet form

    Spero Therapeutics

    Relative Bioavailability

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources